Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is a financially sound company with a strong Q1 performance and potential for external growth in the cardiac market. Their expanding gross margin and international sales strategy, accompanied by investments in R&D and potential acquisitions, showcase their commitment to continued growth and success in the future. However, potential challenges in complying with international regulations and obtaining necessary certifications must be closely monitored.

Bears say

LeMaitre Vascular is experiencing lackluster distribution sales in 2026 due to the discontinuation of Aziyo distribution, which has led to lower-than-average sales and unit pressure. Additionally, while the company has posted record sales in all product categories, they have only seen organical growth of less 12.8% due to lower distribution sales. Lastly, the company has filed for early cannulation labeling with the FDA, but their future financial performance may be impacted by investment in Artegraft and other operational and sales initiatives.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.